GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All comparisons

Ozempic vs Mounjaro in India — For Diabetes and Weight

Last reviewed 12 May 2026 · India-specific clinical evidence

The short answer

Both Ozempic (semaglutide) and Mounjaro (tirzepatide) are DCGI-approved for type 2 diabetes in India, and both also produce significant weight loss. Mounjaro’s dual GIP/GLP-1 mechanism delivers larger HbA1c reductions (1.9–2.6% vs Ozempic’s 1.4–1.8%) and roughly twice the weight loss at maximum dose. Ozempic is approximately half the price. The choice often comes down to diabetes control goals, weight-loss target, and budget.

Not sure which one applies to you?

Take the 5-minute Indian-guideline eligibility check.

Take the free assessment →

Ozempic vs Mounjaro — at a glance

AttributeOzempicMounjaro
Active ingredientSemaglutide (GLP-1)Tirzepatide (GIP + GLP-1)
Primary indication (India)Type 2 DiabetesType 2 Diabetes + Obesity
DCGI approvalPre-2026March 2025
Dose strengths0.25, 0.5, 1, 2 mg weekly2.5, 5, 7.5, 10, 12.5, 15 mg weekly
Maintenance dose for T2D0.5–2 mg weekly5–15 mg weekly
HbA1c reduction (avg, max dose)1.4–1.8% (SUSTAIN)1.9–2.6% (SURPASS)
Mean weight loss (T2D patients)4.5–6.5 kg at 1 mg8.0–15.7 kg at 15 mg
Form factorFlexTouch penKwikPen / vial
Approx. monthly price (India)₹5,660 – ₹9,100₹14,000 – ₹27,500
Indian generics availableYes — 10+ brandsNo (patent-protected)
Cardiovascular outcome dataSELECT (Wegovy data extends)SURPASS-CVOT in progress

Efficacy — what the trials show

Ozempic

Ozempic’s SUSTAIN trials demonstrated mean HbA1c reduction of 1.4–1.8% at 1 mg weekly across patient populations. SUSTAIN-7 directly compared semaglutide to liraglutide (Saxenda/Victoza) — semaglutide won on both glucose and weight outcomes. The 2 mg dose, approved later, extends both benefits. SELECT trial (under Wegovy) showed semaglutide molecule reduces MACE by 20% in patients with established CVD and obesity.

Mounjaro

Mounjaro’s SURPASS trials showed mean HbA1c reductions of 1.9–2.6% across doses (2.5–15 mg), the largest ever observed in T2D injectable monotherapy. SURPASS-2 head-to-head vs semaglutide: tirzepatide produced an additional 0.5% HbA1c reduction at maximum doses and ~6–9 kg additional weight loss. The dual agonist mechanism (GIP + GLP-1) is the proposed driver. Long-term cardiovascular outcomes are under study (SURPASS-CVOT).

Cost in India (2026)

Ozempic

Ozempic costs ₹5,660–9,100/month in India post April 2026 price cuts. The 0.5–1 mg maintenance dose for T2D runs ₹5,500–7,500. Indian generic semaglutides (Sundae, Noveltreat, Obeda, Semaglyn, etc) provide the same molecule at ₹1,290–3,500/month for cost-sensitive patients.

Mounjaro

Mounjaro is the most expensive GLP-1 option in India: ₹14,000–27,500/month. The 5 mg starter dose runs around ₹14,000; 15 mg target dose for weight loss runs ₹25,000+. No Indian generics yet — Eli Lilly’s patent extends several more years.

Side effects

Ozempic

Ozempic’s side effects in T2D patients (SUSTAIN data): nausea 16%, diarrhea 11%, vomiting 8%. Less severe than Wegovy’s obesity-dose profile because T2D patients typically max out at 1 mg. Indian patients report somewhat higher initial GI intolerance during titration, often associated with diet (oily/spicy food). Rare events: pancreatitis, gallbladder disease, retinopathy in poorly controlled diabetics.

Mounjaro

Mounjaro side effects in T2D patients (SURPASS data): nausea 18–22%, diarrhea 16%, vomiting 6–10%, scaling slightly with dose. Despite higher efficacy, GI tolerance is similar to or slightly better than Ozempic. Discontinuation rates due to adverse events: ~5% for Mounjaro, ~4% for Ozempic. Real-world experience in India is shorter than semaglutide.

Which one should you consider?

Pick Ozempic if

  • ✓You have type 2 diabetes with moderate weight component
  • ✓Cost is a significant constraint (or you may switch to a generic)
  • ✓Your doctor has more experience prescribing semaglutide
  • ✓You’re already on a stable HbA1c with diet/metformin and need a moderate boost

Pick Mounjaro if

  • ✓Your HbA1c remains high (>8.5%) despite metformin + lifestyle changes
  • ✓You have both diabetes AND significant weight to lose (BMI ≥30 or comorbidities)
  • ✓You can afford the higher monthly cost
  • ✓You’ve plateaued or had insufficient response to semaglutide

Frequently asked questions

Which lowers HbA1c more, Ozempic or Mounjaro?+
Mounjaro. The SURPASS-2 head-to-head trial showed tirzepatide reduced HbA1c by an additional ~0.5% over semaglutide at maximum doses. In absolute terms: Mounjaro 15 mg → ~2.6% HbA1c reduction vs Ozempic 2 mg → ~1.8%. For patients with persistently high HbA1c (>8.5%) despite other therapy, Mounjaro is generally the more potent option.
Is Mounjaro twice as good as Ozempic for weight loss?+
Roughly yes, at maximum doses. Mounjaro 15 mg in SURMOUNT-1 produced ~22.5% weight loss in non-diabetics; Ozempic 2 mg produces about 10–12%. Important caveat: many T2D patients don’t need (or shouldn’t take) the maximum Mounjaro dose. For someone with BMI ≈ 28 and well-controlled T2D, Ozempic 1 mg may produce 80% of the benefit at half the cost.
Should I take Ozempic or Mounjaro if I have both diabetes and high cholesterol?+
Both reduce cardiovascular risk indirectly via weight + glucose improvement, but Ozempic (via the SELECT/SUSTAIN-6 data on semaglutide) has stronger direct cardiovascular outcome evidence in established CVD. Mounjaro’s SURPASS-CVOT trial is still reading out. For patients with high cardiovascular risk already on statins, semaglutide is currently better-supported by outcomes data.
Can I switch from Ozempic to Mounjaro?+
Yes, and it’s a common path for patients who plateau on semaglutide. The switch isn’t a 1:1 dose match — your doctor will typically restart at Mounjaro 2.5 or 5 mg and re-titrate. Overlapping doses is not recommended. Expect a 2–4-week washout when transitioning, with mild rebound symptoms possible.
Is Mounjaro available as an Indian generic like Ozempic?+
Not yet. Tirzepatide is still patent-protected in India through approximately 2030; only Eli Lilly’s branded Mounjaro is available. Semaglutide (Ozempic’s molecule) went off-patent in India earlier, which is why 10+ Indian generic brands exist. Until Mounjaro’s patent expires, expect the price gap to persist.
For an Indian patient with BMI 32 and pre-diabetes, which is better?+
For pre-diabetes (not yet T2D) with high BMI, weight loss is the priority since it can reverse pre-diabetes. Mounjaro’s larger weight-loss effect is the advantage, IF you can afford it. If budget is a constraint, semaglutide (Ozempic or an Indian generic) at maximum dose is a reasonable choice with strong evidence. Many endocrinologists in India start with semaglutide and switch up to Mounjaro if response is insufficient after 6 months.
Do Ozempic and Mounjaro have the same side effects?+
Similar profile, slightly different intensities. Both cause GI side effects (nausea, diarrhea, vomiting) during titration. Mounjaro’s rates are slightly lower despite higher efficacy. Both carry warnings for pancreatitis, gallbladder issues, and a theoretical thyroid C-cell tumour risk (more characterized for semaglutide due to longer history). Both require titration to minimize side effects.

Related comparisons

Semaglutide vs Tirzepatide

Semaglutide vs Tirzepatide in India — Class-Level Comparison

Mounjaro vs Wegovy

Mounjaro vs Wegovy in India — Which Loses More Weight?

Ozempic vs Wegovy

Ozempic vs Wegovy in India — Which One Do You Actually Need?

Find out which one fits your profile

The 5-minute Indian-guideline assessment uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Start the free assessment →

Information based on DCGI-approved labelling, peer-reviewed trials (STEP, SUSTAIN, SURMOUNT, SURPASS, SELECT), and ESI India clinical guidelines. Always consult a qualified medical practitioner before starting or switching therapy. Both molecules referenced here are Schedule H drugs in India.